Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eng Huat Tan

Showing results (31-40 of 108) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 8, 2019
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinomaRicard Mesia, Paolo Bossi, Aaron R Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderlySwan Swan Leong, Chee Keong Toh, Wan Teck Lim, et al.
Investigative Radiology|May 18, 2011
Dynamic contrast-enhanced computed tomography in metastatic nasopharyngeal carcinoma: reproducibility analysis and observer variability of the distributed parameter modelQuan-Sing Ng, Choon Hua Thng, Wan Teck Lim, et al.
Clinical Lung Cancer|April 9, 2018
A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved SurvivalChee-Keong Toh, Whee-Sze Ong, Wan-Teck Lim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 28, 2004
Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinomaDonald Poon, Swee-Peng Yap, Zee-Wan Wong, et al.
Cancer|December 22, 2004
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combinationSwan-Swan Leong, Joseph Wee, Miah Hiang Tay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
BMC Cancer|December 26, 2018
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastasesWan-Ling Tan, Quan Sing Ng, Cindy Lim, et al.
BMC Cancer|December 5, 2018
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastasesWan-Ling Tan, Quan Sing Ng, Cindy Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2016
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC PatientsNatalia Sutiman, Shao Weng Tan, Eng Huat Tan, et al.
Pageof 11

Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|November 8, 2019
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinomaRicard Mesia, Paolo Bossi, Aaron R Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderlySwan Swan Leong, Chee Keong Toh, Wan Teck Lim, et al.
Investigative Radiology|May 18, 2011
Dynamic contrast-enhanced computed tomography in metastatic nasopharyngeal carcinoma: reproducibility analysis and observer variability of the distributed parameter modelQuan-Sing Ng, Choon Hua Thng, Wan Teck Lim, et al.
Clinical Lung Cancer|April 9, 2018
A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved SurvivalChee-Keong Toh, Whee-Sze Ong, Wan-Teck Lim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 28, 2004
Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinomaDonald Poon, Swee-Peng Yap, Zee-Wan Wong, et al.
Cancer|December 22, 2004
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combinationSwan-Swan Leong, Joseph Wee, Miah Hiang Tay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
BMC Cancer|December 26, 2018
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastasesWan-Ling Tan, Quan Sing Ng, Cindy Lim, et al.
BMC Cancer|December 5, 2018
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastasesWan-Ling Tan, Quan Sing Ng, Cindy Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2016
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC PatientsNatalia Sutiman, Shao Weng Tan, Eng Huat Tan, et al.
Pageof 11